Fujimura, Akiko
Nakayama, Kazunori
Imaizumi, Akira
Kawamoto, Makoto
Oyama, Yasuhiro
Ichimiya, Shu
Umebayashi, Masayo
Koya, Norihiro
Morisaki, Takashi
Nakagawa, Takashi
Onishi, Hideya
Funding for this research was provided by:
KAKENHI (JP15K10055, JP17H04283, JP18K08682)
Article History
Received: 20 February 2019
Accepted: 23 September 2019
First Online: 27 September 2019
Compliance with ethical standards
:
: The authors declare that they have no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Kyushu University Ethics Committee (study approval numbers 29-251 and 28-277) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All procedures performed in studies involving animals were in accordance with the ethical standards of the Animal Care and Use Committee of Kyushu University (study approval numbers A29-376-0 and A29-333-0).
: Written informed consent was obtained from all participants included in the study to the use of their PBMC and tumor specimen for research and for publication before blood collection.
: All mice were obtained from Charles River Laboratories Japan, Yokohama, Japan.
: SUIT-2 is a human pancreatic ductal adenocarcinoma cell line, and SCC-9 is a human tongue squamous cell carcinoma cell line. Both cell lines were purchased from American Type Culture Collection (ATCC) previously and were stored in liquid nitrogen. All cell lines were cultured for no more than 2–3 weeks after thawing, routinely checked for mycoplasma infection while cultured, and showed consistent phenotypes by microscopy prior to in vitro and in vivo experiments.